
In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
By Spencer Johnson Comments are off
In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
Tagged with: BLA, Boehringer Ingelheim, BPCIA, Celltrion, District Court, Genentech, Herceptin®, IPR, Litigation, Mylan, Pfizer, Samsung Bioepsis, Teva, trastuzumab
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
By Seth Cockrum Comments are off
We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
By Seth Cockrum Comments are off
On January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva Pharmaceuticals International...
Tagged with: BPCIA, Celltrion, Genentech, Herceptin®, IPR, News, Patent Dance, Roche, Teva, trastuzumab
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Amgen and Allergan recently announced that they submitted a Biologics License Application (“BLA”) for ABP 980, a proposed biosimilar to...
Tagged with: Allergan, Amgen, Biocon, Celltrion, FDA, Genentech, Herceptin®, Hospira, Mylan, News, Pfizer, Regulatory, Teva, trastuzumab
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Celltrion announced last week that its Biologics License Application (“BLA”) for CT-P10, a biosimilar to Biogen and Genentech’s...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
On May 25, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
Last week, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
On March 31, 2017, Celltrion, Inc. (“Celltrion”) filed three new petition for inter partes review (“IPR”) of two additional patents...
ShareEmail, Linked In, Twitter, Facebook, Google Plus
By C. Nichole Gifford Comments are off
On March 21, 2017, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent Nos....
ShareEmail, Linked In, Twitter, Facebook, Google Plus